Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

41.67USD
21 May 2019
Change (% chg)

$0.08 (+0.19%)
Prev Close
$41.59
Open
$41.71
Day's High
$41.81
Day's Low
$41.49
Volume
20,613,191
Avg. Vol
24,478,769
52-wk High
$46.47
52-wk Low
$35.32

Select another date:

Pfizer's atopic dermatitis treatment meets goals in late-stage study

Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

UPDATE 1-Pfizer's atopic dermatitis treatment meets goals in late-stage study

May 15 Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

Pfizer's dermatitis treatment meets main goals of late-stage study

May 15 Pfizer Inc's dermatitis treatment met the main goals in a late-study, testing the drug in patients aged 12 and older with moderate to severe form of the disease, the drugmaker said on Wednesday.

GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

UPDATE 1-GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

May 9 GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

Australia's anti-trust watchdog gives go-ahead for GSK-Pfizer consumer healthcare deal

May 9 Australia's competition regulator said on Thursday it will not oppose GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business.

Pfizer gets U.S. approval for $225,000 a year heart drug

NEW YORK The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

UPDATE 2-Pfizer gets U.S. approval for $225,000 a year heart drug

NEW YORK, May 6 The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

Pfizer gets U.S. approval for $225,000 a year heart drug

NEW YORK, May 6 The U.S. Food and Drug Administration on Monday approved Pfizer Inc's drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

Select another date: